Merck cedes rights to Parkinson's compounds licensed from Addex

09/5/2011 | PharmaTimes (U.K.)

Merck & Co. ended a partnership with Addex Pharmaceuticals involving the latter's positive allosteric modulators of metabotropic glutamate receptor 4 to treat Parkinson's disease. The licensing deal was formed in 2007 and worth at least $106.5 million in milestone fees. Addex remains committed to developing the compounds for Parkinson's and other indications, said CEO Bharatt Chowrira.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD